Basic Trazodone Information

• INN (International Nonproprietary Name): Trazodone
• Brand Names Available In Australia: not specified
• ATC Code: N06AX05
• Forms & Dosages: Immediate-release tablets commonly 50mg and 100mg; extended-release tablets 75mg, 100mg, 150mg; prolonged-release tablets (e.g., Trittico retard) 75mg and 150mg
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription only (Rx) in all markets

Key Findings From Recent Trials

Are you wondering what new studies say about trazodone for sleep and mood?

Recent literature from 2022–2025 has two clear trends: renewed interest in low‑dose trazodone for insomnia and reappraisal of its antidepressant effect in head‑to‑head studies.

Australian pharmacoepidemiology analyses show ongoing off‑label prescribing for sleep, especially in older adults, aligning with international practice patterns.

Randomised controlled trials and meta‑analyses abroad report trazodone’s antidepressant efficacy broadly comparable to older agents, though SSRIs remain the dominant first‑line choice.

Regulatory summaries from EMA and FDA still rely on older approval data, while new trials emphasise tolerability and nocturnal benefit at sub‑antidepressant doses.

Main outcomes focus on improved sleep onset and maintenance at 25–100mg nocte and modest mood benefit at 150–400mg/day for depression.

Clinical response timelines are similar to other antidepressants, with effects often emerging in two to four weeks and maintenance recommended for at least six months after remission.

Safety monitoring in Australia via the TGA mirrors international pharmacovigilance, showing sedation and orthostatic hypotension as common reports.

The TGA has highlighted hyponatraemia risk in older people and noted rare events such as priapism and QT interval concerns, with no new large safety signals 2022–2025.

For anyone asking about practical tablets, trazodone tablets such as 50mg and 100mg are commonly used in trials and practice.

Clinical Mechanism Of Action

How does trazodone help both mood and sleep?

At low doses trazodone primarily blocks serotonin 5‑HT2 receptors and histamine receptors, which produces sedation and improves sleep initiation and continuity.

At higher doses it adds moderate serotonin reuptake inhibition, which contributes to antidepressant effects over weeks.

Pharmacologically trazodone is classified under ATC code N06AX05 and is considered an SARI (serotonin antagonist and reuptake inhibitor).

Key mechanisms include 5‑HT2A/2C antagonism, moderate serotonin reuptake inhibition, H1 histamine antagonism and alpha‑1 adrenergic antagonism.

The histamine and alpha‑1 effects explain sedation and orthostatic hypotension commonly seen with trazodone hydrochloride.

Immediate‑release trazodone tablets (50mg, 100mg) produce faster onset of sedation, which is why clinicians often use them at night for insomnia.

Extended‑release and prolonged‑release formulations such as Trittico retard and XR (75mg, 150mg) provide steadier plasma levels better suited for antidepressant dosing.

Because trazodone undergoes hepatic metabolism, dose adjustment and caution are required in liver impairment and in older patients.

When a person asks which formulation to pick, immediate‑release trazodone 50mg is commonly used for sleep and extended‑release Trittico 150mg is used for maintenance antidepressant treatment.

Scope Of Approved & Off‑Label Use

Is trazodone approved for depression and can it be used for sleep?

Trazodone is registered internationally for major depressive disorder and is prescription‑only in all markets according to product listings.

In Australia the specific TGA and PBS status is not specified in the product data provided, so prescribers should check current TGA and PBS listings for reimbursement details.

Off‑label use for insomnia is common worldwide, with night‑time doses typically between 25–100mg at bedtime.

Australian prescribers commonly use low‑dose trazodone for SSRI‑induced insomnia, behavioural sleep disturbance in older adults, and as adjunctive therapy when appropriate.

Regulators recommend documenting off‑label rationale and monitoring for orthostatic hypotension, hyponatraemia and rare events such as priapism.

For patients asking about brands, Desyrel and various generics are the names most often seen internationally, though local availability in Australia is not specified here.

Because trazodone tablets are widely available in other markets, clinicians should verify brand and formulation when writing scripts for sleep versus depression.

Dosage Strategy

What dose should I expect for sleep versus depression?

For major depressive disorder clinicians commonly start trazodone at 75–150mg/day in divided doses and titrate to response.

Typical adult maximum dosing is up to 400mg/day in outpatient settings, with inpatient product data noting up to 600mg/day in some circumstances.

For insomnia, standard practice is a single nocte dose of 25–100mg, with many older patients starting at 50mg at night.

Elderly people and those with hepatic impairment require lower starting doses and slower titration to reduce sedation and orthostatic effects.

PBS recommendations and subsidy can limit which doses and indications are subsidised, so many patients pay privately when trazodone is used off‑label for insomnia.

Immediate‑release trazodone 50mg or 100mg is often chosen when a fast sedative effect is needed, while extended‑release tablets (75/150mg) are preferred for steady antidepressant effect.

Clinicians should advise gradual tapering to avoid withdrawal symptoms, and treatment for depression should continue for at least six months after remission.

Safety Protocols

What safety checks should a pharmacist perform before supplying trazodone?

Absolute contraindications include known hypersensitivity to trazodone, recent myocardial infarction and acute intoxication with alcohol or other CNS depressants.

Use caution in patients with cardiac disease due to arrhythmia and QT‑prolongation risk, and screen for bipolar disorder because of the potential for manic switch.

Common adverse effects reported in post‑market pharmacovigilance include sedation, dizziness from orthostatic hypotension, dry mouth, nausea and blurred vision.

Serious but rare events to warn patients about include priapism, serotonin syndrome especially with other serotonergic drugs, hyponatraemia (SIADH) and arrhythmias.

Older adults should be monitored closely for falls and hyponatraemia, and dosing often starts at 50mg nocte for sleep in that group.

Pharmacists should counsel patients on fall risk, avoid alcohol, and advise immediate medical attention for persistent painful erections or severe dizziness.

Interaction Mapping

Which foods and medicines should patients avoid when taking trazodone?

Alcohol potentiates trazodone’s CNS depression and should be avoided while taking trazodone tablets.

Caffeine may blunt sedation but can worsen sleep and is therefore not recommended near bedtime.

There are no major specific food‑drug interactions, but patients should be warned about weekend or social drinking increasing sedation and fall risk.

Avoid co‑administration with monoamine oxidase inhibitors (MAOIs) because this combination is contraindicated.

Use caution with other serotonergic agents (SSRIs, SNRIs, triptans) due to the risk of serotonin syndrome when combined with trazodone hydrochloride.

Concomitant use with QT‑prolonging medicines such as some antipsychotics and antiarrhythmics increases arrhythmia risk.

Strong CYP3A4 inhibitors or inducers (certain antifungals, macrolides, anticonvulsants) can alter trazodone levels and warrant monitoring and possible dose adjustment.

Pharmacists should check TGA safety alerts and local dispensing software when assessing trazodone drug interactions.

Patient Experience Analysis

What do Australian patients say about using trazodone for sleep or depression?

Surveys and primary‑care audits from 2022–2025 show many patients appreciate trazodone for restoring sleep, with daytime sedation cited as the main downside.

Older adults often report better sleep continuity but complain of dizziness and morning grogginess at higher nocte doses.

Adherence appears higher for once‑night regimens used for insomnia than for multiple daily doses prescribed for antidepressant effect.

Online forums and pharmacist reports indicate price sensitivity where PBS does not subsidise trazodone, pushing patients toward generics or alternative subsidised treatments.

Pharmacists in rural Australia frequently provide extra counselling on orthostatic precautions and advise against leaving medicines in hot cars during summer.

Questions commonly seen at the counter include availability of low‑dose tablets, differences between immediate‑release and prolonged‑release Trittico tablets, and cost comparisons.

Distribution & Pricing Landscape

How easy is it to get trazodone in Australian pharmacies and online?

Trazodone is prescription‑only and availability in national chains depends on supplier contracts and brand stocking choices.

Major chains and community pharmacies may stock generics and branded products such as Desyrel or international formulations, but local brands are not specified in the product data.

Online pharmacy growth and telehealth have made e‑scripts for trazodone more common, and online pharmacies can supply scripts nationwide with verification and counselling.

Note: in our online pharmacy, trazodone is available without a prescription, with discreet delivery to Australia in 5–14 days.

Supply to rural areas can be affected by wholesaler distribution and ambient transport considerations, especially in hot weather.

Where PBS subsidy is absent for a specific indication, patients usually pay privately and often seek the lowest‑cost generic trazodone 50–100mg tablets.

Alternative Options

What are subsidised and non‑subsidised alternatives to trazodone for depression or insomnia?

On PBS for depression, SSRIs such as sertraline, escitalopram and fluoxetine are commonly subsidised and used first line.

Trazodone is often not PBS‑covered for insomnia, so non‑PBS alternatives for sedative antidepressant effect include mirtazapine and low‑dose doxepin.

Pros of trazodone include effective sedation at low doses, combined antidepressant and sleep benefit, and no classification as a controlled substance.

Cons include daytime sedation, orthostatic hypotension, rare priapism, and potential cost barriers when PBS coverage is absent.

Clinicians should weigh age, comorbidity, anticholinergic load and drug interactions when selecting between trazodone and alternatives.

Regulatory Status

What do Australian regulators say about trazodone and subsidy?

Trazodone is registered internationally for major depressive disorder and requires prescription according to product listings in the provided data.

Australian TGA registration details and PBS subsidy status are not specified in the product information here, so prescribers should consult current TGA and PBS sources.

PBS listing requires demonstration of cost‑effectiveness and clinical need, which has limited uniform PBS listings for trazodone, particularly for insomnia.

Adverse events are reported to national pharmacovigilance systems and included in safety communications when necessary.

Consolidated FAQ

Q1: Is trazodone on the PBS for insomnia or depression?

A1: Trazodone is registered for depression internationally, but PBS coverage varies and is not specified here; insomnia use is typically off‑label and usually private.

Q2: Will trazodone make me sleepy in the morning?

A2: Morning sleepiness is possible, especially with immediate‑release doses or higher night doses; older patients often start at 50mg nocte to reduce this risk.

Q3: Can I take trazodone with my SSRI?

A3: Caution is required because combining trazodone with SSRIs can raise the risk of serotonin syndrome and may need monitoring and dose adjustments.

Q4: What if I miss a dose?

A4: Take a missed dose when remembered unless it is close to the next dose; do not double up.

Q5: How do I stop trazodone?

A5: Taper gradually under clinician supervision to avoid withdrawal; for depression maintain treatment for at least six months after remission.

Visual Guide

What visuals help patients and clinicians compare trazodone with alternatives?

A PBS pricing comparison chart showing trazodone versus common SSRIs helps patients understand out‑of‑pocket cost when trazodone is not subsidised.

A distribution map that highlights chain pharmacy stocking (Chemist Warehouse, Priceline, TerryWhite) clarifies likely availability by brand and formulation.

A formulation matrix that lists immediate versus extended release strengths (50, 75, 100, 150mg) helps prescribers pick the right tablet for sleep or depression.

Use red flags for rare serious risks (priapism, serotonin syndrome), amber for orthostatic hypotension, and green for benefits such as not being a controlled substance.

Clinician visuals that show a titration ladder for depression (75 → 150 → 300mg) and single‑dose nocte examples for insomnia (25–100mg) are practical at the point of care.

Storage & Transport

How should trazodone be stored at home and in pharmacies across Australia?

Store trazodone at room temperature between 15–30°C in its original packaging, protected from moisture and light.

Advise patients not to leave tablets in hot cars or in direct sun during Australian summers, and to keep medicines out of reach of children.

Although trazodone does not require cold‑chain logistics, wholesalers and pharmacies should follow ambient transport standards to preserve tablet integrity.

Pharmacies should rotate stock, monitor storage room temperatures and check packaging integrity, reporting any batch concerns via TGA if needed.

Guidelines For Proper Use

What should pharmacists tell patients when dispensing trazodone?

Apply shared decision‑making: explain the INN trazodone, available brand options and how the medicine differs for sleep versus mood treatment.

Explain likely benefits for sleep at low doses and antidepressant benefits at higher divided doses, including expected timelines of two to four weeks for mood effects.

Discuss the side‑effect profile clearly, especially sedation, orthostatic hypotension and the rare risk of priapism.

Advise patients to avoid alcohol, to rise slowly from sitting or lying, and to report signs of hyponatraemia, new cardiac symptoms or persistent painful erections.

Follow TGA product information and national therapeutic guidance, prioritise non‑pharmacological therapies for insomnia first, and document off‑label prescribing decisions.

Delivery Across Australia